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ABSTRACT
Introduction: In patients with conduction
abnormalities or left ventricle (LV) dysfunction
the use of b-blockers for post cardiac surgery
rhythm control is difficult and controversial,
with a paucity of information about other drugs
such ivabradine used postoperatively. The
objective of this study was to compare the
efficacy and safety of ivabradine versus
metoprolol used perioperatively in cardiac
surgery patients with conduction
abnormalities or LV systolic dysfunction.
Methods: This was an open-label, randomized
clinical trial enrolling 527 patients with
conduction abnormalities or LV systolic
dysfunction undergoing coronary artery bypass
grafting or valvular replacement, randomized to
take ivabradine or metoprolol, or metoprolol
plus ivabradine. The primary endpoints were
the composites of 30-day mortality, in-hospital
atrial fibrillation (AF), in-hospital three-degree
atrioventricular block and need for pacing, in-
hospital worsening heart failure (HF; safety
endpoints), duration of hospital stay and
immobilization and the above endpoint plus
in-hospital bradycardia, gastrointestinal
symptoms, sleep disturbances, cold extremities
(efficacy plus safety endpoint).
Results: Heart rate reduction and prevention of
postoperative AF or tachyarrhythmia with
combined therapy was more effective than
with metoprolol or ivabradine alone during
the immediate postoperative management of
cardiac surgery patients. In the Ivabradine
group, the frequency of early postoperative
pacing and HF worsening was smaller than in
the Metoprolol group and in combined therapy
group. The frequency of primary combined
endpoint was lower in the combined
Ivabradine ? Metoprolol group compared with
the monotherapy groups.
Electronic supplementary material The online
version of this article (doi:10.1007/s40119-013-0024-1)
contains supplementary material, which is available to
authorized users.
L. Iliuta  M. Rac-Albu (&)
‘‘Carol Davila’’ University of Medicine and
Pharmacy, Bucharest, Romania
e-mail: racalbu@yahoo.com
Enhanced content for this article is
available on the journal web site:
www.cardiologytherapy-open.com
123
Cardiol Ther (2014) 3:13–26
DOI 10.1007/s40119-013-0024-1
Conclusion: Considering efficacy and safety, the
cardiac rhythm reduction after open heart surgery
in patients with conduction abnormalities or LV
dysfunction with ivabradine plus metoprolol
emerged as the best treatment in this trial.
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Postoperative arrhythmias are serious and
common complications following open heart
surgery and are associated with increased
morbidity and mortality [1]. Older age is the
most consistent predictor of postoperative atrial
arrhythmias [1]. Atrial fibrillation (AF) is the
most common arrhythmia encountered
postoperatively [1], with a reported incidence
from 20 to 40%, although ventricular
arrhythmias and conduction disturbances can
also occur [2]. Patients who develop
postoperative arrhythmias are more likely to
have other postoperative complications such as
perioperative myocardial infarction, congestive
heart failure (HF), respiratory failure and
increased hospital length of stay and costs [3–
9]. Recent studies report incidences of atrial
arrhythmias after coronary artery bypass
grafting (CABG) surgery to be 17–33% [3–8],
and even higher after valvular surgery [4].
While postoperative atrial fibrillation (POAF)
can be transient and without consequences, it
may lead to serious complications such as
increased risk of acute kidney injury,
hemodynamic instability, cardiac failure, stroke,
and death [2]. In spite of older age being still the
most consistent predictor of postoperative AF,
factors such as acute atrial changes occurring at
the time of surgery (acute atrial enlargement,
intraoperative atrial ischemia), hypertension,
trauma from cannulation, hypomagnesaemia,
inflammation caused by pericarditis,
cardiopulmonary bypass and cross-clamp times,
pulmonary vein venting and also excessive
adrenergic stimulation, are incriminated in its
occurrence in vulnerable patients [9–15].
Postoperative atrial fibrillation is most often
detected on the second and third day
postoperatively [12–15] and is frequently self-
limiting and short-lived. Up to 80% of patients
convert to sinus rhythm (SR) within 24 h, and
6 weeks after initial diagnosis 98% of patients
have converted to SR [5].
Patients developing postoperative AF are
more likely to have prolonged hospitalization
and intensive care unit (ICU) stay and therefore,
increased economic burden of their care [7, 8].
Despite the identification of risk factors and
efforts to determine effective prophylactic
agents, postoperative atrial arrhythmias
remain a prominent clinical issue.
The meta-analyses and systematic reviews for
prevention of postoperative rhythm disorders
showed that interventions to prevent and/or
treat postoperative AF with b-blockers, sotalol or
amiodarone and, less convincingly, override
suppression of automatic atrial foci by atrial
pacing, are favored with respect to outcome (AF
occurrence, stroke, and length of hospitalization)
[16–21]. Despite multiple randomized studies
demonstrating the consistent prophylactic
effectiveness of b-blockers [16–21], in most trials,
b-blockers have been used only in a limited
manner, presumably because of fear of
hemodynamic or pulmonary intolerance and
excluding patients with significant obstructive
lung disease, atrioventricular (AV) block greater
than first degree and impaired left ventricle (LV)
function [9, 22].
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Because the use of b-blockers is difficult and
controversial in patients with conduction
abnormalities, severe LV dysfunction, active
bronchospasm, there is a need for another
drug for rhythm control in postoperative
cardiac surgical patients.
The selective If current inhibitor ivabradine
reduces heart rate without affecting cardiac
contractility by selective sinus node
inhibition, and has been shown to be cardio
protective in the failing heart [23].
Ivabradine showed improvement of clinical
outcomes in patients with stable coronary artery
disease and LV systolic dysfunction [24] or
chronic HF [23]. However, there are few
published data from clinical trials which
evaluated the efficacy and benefits of Ivabradine
used postoperatively in patients with conduction
abnormalities or LV dysfunction undergoing
coronary surgery for prevention or treatment of
postoperative rhythm disorders [25].
Ivabradine also exerts some of its beneficial
effects by decreasing cardiac proinflammatory
cytokines and inhibiting peroxidants and
collagen accumulation in atherosclerosis or
congestive heart failure [26].
The main objectives of our study were to
compare the efficacy and safety of heart rate
lowering agent ivabradine versus b-blocker
metoprolol used perioperatively in patients
undergoing cardiac surgery and having
conduction abnormalities (first degree AV block
or bundle branch block) or LV dysfunction and
also to determine whether prophylactic therapy
with ivabradine can reduce hospital stay and
economic costs after cardiac surgery by lowering
the risk associated with an increased heart rate.
METHODS
This clinical trial was open-label, randomized,
enrolling 527 patients undergoing cardiac
surgery (CABG with arteries–internal
mammary, radial, gastroepiploic–or inverted
saphenous veins, valvular replacement or
combined interventions) in a single center
(Cardiac Surgery Department of Emergency
Institute for Cardiovascular Diseases ‘‘Prof. Dr.
C. C. Iliescu’’, Bucharest, Romania) between
January 1, 2006 and December 31, 2010.
Surgical management and treatment of the
patients were based on a common standard
protocol.
The study was not registered with any
international body prior to commencement.
Eligibility Criteria
Patients included in the clinical trial were
patients undergoing elective cardiac surgery
interventions who had conduction
abnormalities, LV systolic dysfunction or both.
At the moment of the enrolment into the study
all patients were in sinusal rhythm.
Exclusion Criteria
Not eligible for the study were the patients
exhibiting one or more of the following
conditions: third degree AV block; bradycardia
[heart rate less than 50 beats per minute (bpm)]
or conditions associated with increased risk for
bradycardia (vagal predominance, sick sinus
syndrome); HF New York Heart Association
(NYHA) class IV; cardiogenic shock; severe
chronic obstructive pulmonary disease or
pulmonary impairment; known
hypersensitivity to b-blockers or ivabradine;
active participation in another clinical trial;
failure to comply with the hospital protocol or
absence to follow-up.
Study drop-out criteria included the
occurrence of adverse events: severe
bradycardia, skin reactions, gastrointestinal
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symptoms, cold extremities. The study protocol
was approved by the institute Management and
Ethics Committee. All procedures followed were
in accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients for being included in
the study.
Study Groups
After inclusion in the study, 2 days before
surgery, patients were randomized in three
groups: Metoprolol group: 176 patients to
receive metoprolol 100 mg orally once daily;
Metoprolol ? Ivabradine group: 179 patients to
receive metoprolol 50 mg orally once daily and
ivabradine 5 mg orally twice daily; Ivabradine
group: 172 patients to receive ivabradine 5 mg
orally twice daily. During the postoperative nil
by mouth period ivabradine was administered
via nasogastric tube. The treatment phase
comprised 2 days preoperatively and at least
10 days postoperatively and the patients were
followed up for 30 days after surgery (Fig. 1).
The study drug was withdrawn in patients who
developed postoperative AF as there is no effect
of ivabradine on heart rate in this situation.
Clinical and Laboratory Assessments
Patients were evaluated at baseline (i.e., 2 days
before surgery), daily from Day 1 until Day 10
postoperatively, on Day 15, and at the end of
the treatment on Day 30 postoperatively.
Patients with short in-hospital evolution were
evaluated ambulatory.
Clinical parameters included NHYA class,
ventricular rhythm, patient compliance, and
quality of life (QOL). QOL was measured by the
EuroQol questionnaire [27].
Laboratory parameters assessed were: usual
blood tests (white and red blood cell count,
platelet count, hemoglobin, hematocrit,
alanine aminotransferase and aspartate
aminotransferase, lactate dehydrogenase,
blood chemistry), electrocardiogram (ECG)
(with the evaluation of rhythm and rate), 24 h
ECG Holter monitoring and echocardiographic
measurements of the LV dimensions, LV
systolic and diastolic performance, left atrium
dimensions and compliance (data not shown in
the present report). Cardiac rhythm was
continuously monitored in the intensive care
unit. During further hospital stay, subsequent
ECG tests and a 24 h ECG Holter monitoring
was carried out prior to discharge.
Follow-up visits were in Day 15 and in Day
30 postoperatively and included a physical
examination and a 15-min interview, a resting
ECG, an echocardiogram and a 24 h ECG Holter
monitoring. Early episodes of HF were
diagnosed based on clinical signs and
symptoms and by transthoracic and
transesophageal echocardiography. The
presence of bradycardia or second or third
degree AV block was assessed using clinical
examination, resting ECG and 24 h ECG Holter
monitoring.
Fig. 1 Study phases and distribution of study population.
Minim at least, pts patients
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Study Endpoints
The efficacy endpoints were 30-day mortality,
in-hospital occurrence of AF/arrhythmias, in-
hospital occurrence of third degree AV block
and need for pacing, in-hospital worsening
heart failure and duration of hospitalization
and immobilization. Safety endpoints were
occurrence of bradycardia, gastrointestinal
complaints, sleep disturbances, and cold
extremities. A composite efficacy and safety
endpoint including 30-day mortality, in-
hospital AF/arrhythmias, in-hospital AV block/
need for pacing, or in-hospital heart failure
worsening was also defined.
Statistical Analyses
No sample size assumptions have been made
for this trial. Continuous variable are
presented as mean ± standard deviation.
Categorical variables are displayed as
percentages. To analyze the differences
between the treatment groups, the Student’s
t test was used for the continuous variables
and the Chi square test for the categorical
variables. For each endpoint, a two-sided 95%
confidence interval was calculated and an
overall Chi square test comparing the two
treatment groups was used. Also, we
performed simple and multivariate, linear
and logistic regression analysis and we
calculated relative risks and correlation
coefficients. For the primary endpoints
Kaplan–Meier curves were constructed and
log-rank tests were used. All statistical
analyses were performed using SYSTAT 12
(Systat Software, Inc., IL, USA) and SPSS
Statistics 18 (IBM Corporation, NY, USA)
software. A P value less than 0.05 defined
the statistical significance.
RESULTS
In the entire study population, mean age was
63 ± 8 years, and 40.99% of patients were
female. Baseline demographics and clinical
characteristics of the three treatment groups
are displayed in Table 1.
There were no differences in age and gender
of patients, presence of LV dysfunction or
conduction abnormalities between study
groups, systolic blood pressure or mean
baseline heart rate, mean number of grafts/
patient and grafts type, type of valvular
replacement, risk score for atrial arrhythmias
and mean treatment duration. The percentages
of patients with previous episodes of AF, with
LV dysfunction and conduction abnormalities
(first degree AV block, complete left bundle
branch block, bifascicular and trifascicular
block) were similar in the three groups.
Study groups structure depending on the
type of the surgical intervention and on the
type of the relative contraindication to b-
blockers is presented in Fig. 2.
The primary efficacy and safety, single and
composite endpoints in the treatment groups
are shown in Table 2.
In-hospital postoperative AF or
tachyarrhythmias occurred less frequently with
combined therapy (metoprolol and ivabradine)
than with metoprolol or ivabradine alone
(P\0.001). The associated relative risk showed
a higher protective value for the occurrence of
postoperative AF in patients undergoing cardiac
surgery interventions treated with combined
therapy compared with metoprolol
monotherapy (-2.9 versus -1.8; Fig. 3).
In the Ivabradine group, the frequency of early
postoperative third degree AV block or need for
pacing and also the frequency of HF worsening
was lower than in the Metoprolol group and in the
combined Metoprolol ? Ivabradine group
Cardiol Ther (2014) 3:13–26 17
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(P\0.0001; Table 2). Also, the associated relative
risks for early postoperative complete AV block or
need for permanent pacing and for postoperative
HF worsening were lower in ivabradine-treated
groups (Fig. 3).
The rates of combined efficacy plus safety
endpoints (30-day mortality, in-hospital AF/
arrhythmias, in-hospital AV block/need for
pacing, or in-hospital HF worsening) were
lower in the combined therapy group versus
metoprolol or ivabradine monotherapy groups
(P\0.0001; Table 2).
The overall QOL was better in the Ivabradine
group. Ivabradine-treated patients had
shortened hospital stay (the mean duration of
hospital stay in the Metoprolol group was
10.2 ± 6.3 days, compared to 8.5 ± 6.8 days in
the Metoprolol ? Ivabradine group and
8.2 ± 6.4 days in the Ivabradine group), and
reduced immobilization duration in the
immediate postoperative period (2.0 ± 3.0 days
in the Metoprolol group, 1.1 ± 3.0 days in the
Metoprolol ? Ivabradine group and
1.1 ± 3.0 days in the Ivabradine group). Also,
the percent of the patients with hospitalization
duration [15 days or with immobilization
period [3 days was smaller in the combined
Metoprolol ? Ivabradine group (P\0.005;
Table 2). The cumulative incidence of non-
cardiac side effects (sleep disturbances,







N5 176 N5 179 N5 172
Age (years) 63 (12) 63 (12) 63 (13)
Percentage female 39.77% 40.78% 42.44%
Weight (kg) 76 (16) 75 (14) 77 (13)
Height (cm) 171 (9) 173 (10) 170 (8)
Mean heart rate (over 24 h) 81 (15) 80 (16) 79 (14)
LV systolic dysfunction 42.61% 43.02% 44.19%
Conduction abnormalities 39.77% 39.66% 38.37%
LV dysfunction and conduction abnormalities 17.61% 17.32% 17.44%
Previous episodes of atrial arrhythmias 20.45% 20.11% 20.35%
Hypertension 65.34% 65.92% 68.60%
Diabetes mellitus 28.98% 29.61% 27.33%
Re-intervention–previous CABG 9.66% 10.05% 9.30%
Re-intervention–previous valve replacement 2.27% 2.23% 3.49%
CABG 59.66% 60.33% 59.30%
Valve replacement 32.39% 32.40% 33.72%
CABG and valve replacement 7.95% 7.26% 6.98%
CABG coronary artery bypass grafting, LV left ventricle
a Parameters are expressed as mean values (standard deviation) or percentages. All P values for comparisons between groups
were not signiﬁcant
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gastrointestinal symptoms, and skin reactions)
was similar in the study groups (Table 2).
The superiority of ivabradine (efficacy and
safety) was also shown by Kaplan–Meier curves
generated for the primary endpoints in both
groups (ivabradine as monotherapy and
combination therapy ivabradine plus
metoprolol), log-rank tests being highly
significant between days 4–30 of treatment
(Fig. 4).
In Fig. 3 we indicate associated relative risks
in ivabradine-treated groups (with or without
metoprolol) comparative with Metoprolol
group after cardiac surgery according to type
of surgical intervention, preoperative
conduction abnormalities, previous episodes of
AF, NYHA class, grafts number, and age. It is
obvious the superiority of ivabradine (as
monotherapy or combined therapy with
metoprolol) versus metoprolol therapy alone
in terms of efficacy and safety endpoint of
30-day mortality, in-hospital HF worsening, in-
hospital AF/arrhythmias or in-hospital AV
block/need for pacing.
DISCUSSION
The present study is one of the first studies that
evaluated the efficacy and safety of ivabradine
therapy for prevention of postoperative AF or
other tachyarrhythmias in patients undergoing
coronary or valvular surgery. Prevention of
Fig. 2 Study groups structure. CABG coronary artery bypass grafting. LV left ventricle
Cardiol Ther (2014) 3:13–26 19
123
postoperative rhythm disorders immediately
after cardiac surgery becomes increasingly
important because they are associated with
longer ICU and hospital stays (up to 5 days)
[28, 29], significantly higher (two to threefold)
risk of postoperative stroke [28–31], increased
morbidity and mortality, with consecutively
important economic burden of these
outcomes. Although the overall topic of AF
after cardiac surgery was evaluated in a lot of
clinical trials, still, there is a relative paucity of
evidence-based studies dealing with
pharmacologic heart rhythm control
addressing this topic [31].







N5 176 (%) N5 179 (%) N5 172 (%)
30-day mortality, in-hospital AF/arrhythmias 13.64 12.85 23.84
30-day mortality, in-hospital AF/arrhythmias, in-hospital
AV block/need for pacing, or in-hospital HF worsening
34.09 23.46 29.07
Death at 30 days 3.98 3.91 4.07
In-hospital AF/arrhythmias 9.66 8.94 19.77
In-hospital 3 degree AV block/need for pacing 12.50 6.15 2.91
In-hospital HF worsening 7.95 4.47 2.33
Hospitalization duration[15 days 33.52 17.88 23.26
Immobilization for[3 days 25.00 16.76 22.67
Sleep disturbances/gastrointestinal symptoms/skin reactions 3.41 3.35 3.49
AF atrial ﬁbrillation, AV atrioventricular, HF heart failure
Fig. 3 The relative risks of ivabradine and combined
therapy with ivabradine and metoprolol versus metoprolol
monotherapy for early postoperative atrial ﬁbrillation,
complete atrioventricular block/need for pacing and post-
operative heart failure worsening. AV atrioventricular
20 Cardiol Ther (2014) 3:13–26
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Atrial fibrillation is the most common
complication which occurs after cardiac
surgery, with frequencies ranging from 30%
after coronary artery bypass grafting, 40% after
valve surgery, and 50% after combined
coronary artery bypass grafting/valve surgery
[9]. Development of AF immediately after
coronary artery bypass grafting or after valve
surgery or combined requires a longer period of
hospitalization [28, 29], an increased risk (two
to threefold) of postoperative stroke [28, 30]
and also it independently predict postoperative
delirium and neurocognitive decline [17]. The
risk categories for POAF include those with
prolonged cross-clamp time, chronic
obstructive pulmonary disease, advanced age,
atrial ischemia, proximal right coronary artery
disease, and withdrawal of beta-blockers
(should be avoided before surgery being a
significant risk factor for POAF) [9].
At present, b-blockers are the mainstay of
therapy for prevention of postoperative AF in
cardiac surgery being recommended both by the
American College of Cardiology/American
Heart Association (ACC/AHA) 2004 Guideline
update for CABG surgery and by the most recent
European Society of Cardiology (ESC) guidelines
for the management of AF as a class I indication
in the prophylactic management of POAF in
patients without contraindications to b-blocker
therapy [9, 22].
Studies showed that withdrawal of beta-
blockers in the perioperative period doubles
the incidence of PAOF after coronary artery
bypass grafting [22]. Virtually every study of
beta-blockers administered for the purpose of
reducing POAF has shown benefit in this regard,
even if data regarding improvement of hospital
stay or reduction of stroke incidence are still
controversial [16]. Most beta-blockers trials
have examined the initiation of prophylaxis in
the postoperative period. But it seems to be an
even greater benefit if beta-blocker therapy is
initiated before surgery. That is why the ESC
guidelines for the management of AF
recommend that treatment should be started
at least 1 week before surgery with a beta1-
blocker without intrinsic sympathomimetic
activity [9].
The b-blockers used in studies assessing AF
prevention in cardiac surgery were propranolol
[19], atenolol [32], metoprolol [18, 21],
Fig. 4 Kaplan–Meier curves for the composite endpoint of
30-day mortality, in-hospital atrial ﬁbrillation/arrhythmias,
in-hospital atrioventricular block/need for pacing, or in-
hospital heart failure worsening in the three treatment
groups: ivabradine alone versus combined ivabradine plus
metoprolol and metoprolol alone. BAV atrioventricular
block, HF heart failure
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carvedilol [33, 34], acebutolol [35], timolol [36],
betaxolol [16], compared to control or to
another b-blocker.
Also, sotalol was used for the prevention of
AF in cardiac surgery, showing to reduce the
incidence of postoperative AF [14, 20] compared
to placebo or to other b-blocker such as atenolol
[37], metoprolol [38] or propranolol [39] but it
had no impact on the length of hospital stay,
risk of strokes or mortality.
Because of its important side effects
(bradycardia and torsade de pointes), the use
of sotalol in the treatment of POAF is limited,
especially in patients with electrolyte
disturbances. This is why sotalol has class IIb
indication, according to ESC guidelines for AF
prevention in cardiac surgery patients [9].
The use of amiodarone is also beneficial for
the postoperative prevention of atrial
arrhythmias, reducing the length of
hospitalization, decreasing the incidence of
postoperative AF, stroke, and postoperative
ventricular tachyarrhythmia, being without
effect on postoperative mortality [40].
The use of b-blockers or other
antiarrhythmic drugs is limited in some
patient’s subgroups with severe LV
dysfunction and active bronchospasm or
having cardiac conduction abnormalities. In
this case, ivabradine, a specific inhibitor of the
If current in the sinoatrial node can be an
optimal alternative. Ivabradine is a pure heart-
rate lowering agent in patients with sinus
rhythm, the main advantage being that
ivabradine does not affect myocardial
contractility, blood pressure, intracardiac
conduction, or ventricular repolarisation.
In the BEAUTIFUL study (patients with
coronary artery disease and LV systolic
dysfunction–left ventricular ejection fraction
of less than 40%), ivabradine reduced the
incidence of endpoints related to coronary
artery disease (admission to hospital for fatal
and non-fatal acute myocardial infarction) [24].
Ivabradine, also can be used in conjunction
with b-blockers in patients with coronary artery
disease and impaired LV systolic function, this
combination showing an improvement on
coronary artery disease outcomes in patients
with heart rates of 70 bpm or more [24]. These
results suggest that further lowering of heart
rate has beneficial effects on coronary disease
outcomes [24].
In the SHIFT study, performed in patients
with stable symptomatic chronic HF and a LV
ejection fraction of 35% or lower, with a resting
heart rate of 70 bpm or higher, ivabradine
added to optimal standard treatment
significantly reduced major risks associated
with HF: cardiovascular death or hospital
admission for worsening HF [23].
The results of these two studies supporting
the importance of heart rate reduction with
ivabradine for improvement of clinical
outcomes in HF or coronary artery disease
with systolic LV dysfunction were the
rationale for using ivabradine alone or in
combination with metoprolol for prevention
of postoperative rhythm disorders and
reduction of subsequent morbidity, mortality
and associated economic costs in patients with
conduction abnormalities or LV systolic
dysfunction undergoing open heart surgery
[20, 21].
Ivabradine is a new and safe alternative to
decrease heart rate in postoperative cardiac
surgery patients, without affecting blood
pressure; it allows us to reduce the heart rate
in a group of patients in whom side effects of
‘‘target doses’’ of b-blockers are a major concern.
To decrease the oxygen consumption and to
reduce heart rate is the target in the immediate
postoperative period and that cannot be
obtained in all patients by increasing the b-
22 Cardiol Ther (2014) 3:13–26
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blockers. That is the role of ivabradine’s use in
different indication in the postoperative period
of cardiac surgery patients who developed
tachyarrhithmias or AF which could not be
controlled by b-blocker due to conduction
abnormalities, LV systolic dysfunction or
hypotension with b-blocker therapy.
In our case, it was more effective the use of
combined therapy (ivabradine and metoprolol)
for the prevention of POAF and other
tachyarrhythmias than monotherapy with
metoprolol or ivabradine alone in the
postoperative period for the patients with
CABG or valvular replacement.
The patients treated with ivabradine
improved the QOL, shortened the
hospitalization stay, and shortened the time of
immobilization in the postoperative period. It
also decreased the incidence of supraventricular
or ventricular arrhythmias.
Because of the association of AF and other
postoperative tachiarrhythmias with increased
morbidity and mortality and longer, more
expensive hospital stays, we also defined a
composite efficacy and safety endpoint of
30-day mortality, in-hospital AF/arrhythmias,
in-hospital AV block/need for pacing, or in-
hospital HF worsening. Ivabradine as
monotherapy or in combination with
metoprolol was superior to metoprolol in
respect to the composite efficacy and safety
endpoints for prevention of rhythm control and
prevention of rhythm disorders after cardiac
surgery.
Study Limitations
The absence of a washout period–b-blocker
therapy was not stopped before the
randomization, 85% of our patients having
preoperative b-blocker therapy. The practice in
our department was to routinely continue
preoperative b-blocker therapy without any
pause and changing the active principle
according to the study group.
About 30% of the patients with previous
episodes of AF received prior to the inclusion in
the study an antiarrhythmic agent such as
amiodarone or sotalol.
Because 85% of our patients were treated
with b-blockers before entering the study, it is
possible that the results to be influenced,
meaning that the effect of ivabradine be
superior to metoprolol in the first 2 days at
baseline (the time of removal of metoprolol is
15–35 h). The lack of a washout period for
patients on beta-blocker at time of study entry
may have a minor influence results in terms of
overrating of ivabradine in the first 2 days of the
study, while it lasts metoprolol elimination.
Given these limitations, the study can be
considered exploratory and hypothesis
generating.
CONCLUSION
The QOL (measured by the EuroQol
questionnaire) was improved in patients
treated with ivabradine combined with
metoprolol due to shortened immobilization
during the immediate postoperative period
(2.0 ± 3.0 days in the Metoprolol group,
1.1 ± 3.0 days in Metoprolol ? Ivabradine
group), shorter hospital stay (in the
Metoprolol group was 10.2 ± 6.3 days,
compared to 8.5 ± 6.8 days in Metoprolol ?
Ivabradine group), less atrial or ventricular
arrhythmias (cardiac rhythm was continuously
monitored in the ICU. During further hospital
stay, subsequent ECG tests and a 24 h ECG
Holter monitoring was carried out prior to
discharge), less worsening HF, less need for
Cardiol Ther (2014) 3:13–26 23
123
permanent pacing, as well as due to lack of
significant side effects.
The heart rate reduction in the early
postoperative period after cardiac surgery in
patients with conduction abnormalities or LV
dysfunction with combined ivabradine and
metoprolol therapy emerged as the best
treatment in this trial, considering the
ivabradine efficacy and safety profile.
As a final conclusion, ivabradine is an
attractive alternative pharmacological strategy
for rhythm and heart rate control in the early
postoperative period in patients undergoing
open heart surgery (CABG and/or valvular
replacement) with relative or absolute
contraindications to b-blocker therapy.
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